Skip to main content
construction release_alert
Scholars@Duke will be undergoing maintenance April 11-15. Some features may be unavailable during this time.
cancel

VEGF inhibition and renal thrombotic microangiopathy.

Publication ,  Journal Article
Eremina, V; Jefferson, JA; Kowalewska, J; Hochster, H; Haas, M; Weisstuch, J; Richardson, C; Kopp, JB; Kabir, MG; Backx, PH; Gerber, H-P ...
Published in: N Engl J Med
March 13, 2008

The glomerular microvasculature is particularly susceptible to injury in thrombotic microangiopathy, but the mechanisms by which this occurs are unclear. We report the cases of six patients who were treated with bevacizumab, a humanized monoclonal antibody against vascular endothelial growth factor (VEGF), in whom glomerular disease characteristic of thrombotic microangiopathy developed. To show that local reduction of VEGF within the kidney is sufficient to trigger the pathogenesis of thrombotic microangiopathy, we used conditional gene targeting to delete VEGF from renal podocytes in adult mice; this resulted in a profound thrombotic glomerular injury. These observations provide evidence that glomerular injury in patients who are treated with bevacizumab is probably due to direct targeting of VEGF by antiangiogenic therapy.

Duke Scholars

Altmetric Attention Stats
Dimensions Citation Stats

Published In

N Engl J Med

DOI

EISSN

1533-4406

Publication Date

March 13, 2008

Volume

358

Issue

11

Start / End Page

1129 / 1136

Location

United States

Related Subject Headings

  • Vascular Endothelial Growth Factor A
  • Thrombosis
  • Signal Transduction
  • Renal Circulation
  • RNA, Messenger
  • Proteinuria
  • Podocytes
  • Neoplasms
  • Middle Aged
  • Microcirculation
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Eremina, V., Jefferson, J. A., Kowalewska, J., Hochster, H., Haas, M., Weisstuch, J., … Quaggin, S. E. (2008). VEGF inhibition and renal thrombotic microangiopathy. N Engl J Med, 358(11), 1129–1136. https://doi.org/10.1056/NEJMoa0707330
Eremina, Vera, J Ashley Jefferson, Jolanta Kowalewska, Howard Hochster, Mark Haas, Joseph Weisstuch, Catherine Richardson, et al. “VEGF inhibition and renal thrombotic microangiopathy.N Engl J Med 358, no. 11 (March 13, 2008): 1129–36. https://doi.org/10.1056/NEJMoa0707330.
Eremina V, Jefferson JA, Kowalewska J, Hochster H, Haas M, Weisstuch J, et al. VEGF inhibition and renal thrombotic microangiopathy. N Engl J Med. 2008 Mar 13;358(11):1129–36.
Eremina, Vera, et al. “VEGF inhibition and renal thrombotic microangiopathy.N Engl J Med, vol. 358, no. 11, Mar. 2008, pp. 1129–36. Pubmed, doi:10.1056/NEJMoa0707330.
Eremina V, Jefferson JA, Kowalewska J, Hochster H, Haas M, Weisstuch J, Richardson C, Kopp JB, Kabir MG, Backx PH, Gerber H-P, Ferrara N, Barisoni L, Alpers CE, Quaggin SE. VEGF inhibition and renal thrombotic microangiopathy. N Engl J Med. 2008 Mar 13;358(11):1129–1136.

Published In

N Engl J Med

DOI

EISSN

1533-4406

Publication Date

March 13, 2008

Volume

358

Issue

11

Start / End Page

1129 / 1136

Location

United States

Related Subject Headings

  • Vascular Endothelial Growth Factor A
  • Thrombosis
  • Signal Transduction
  • Renal Circulation
  • RNA, Messenger
  • Proteinuria
  • Podocytes
  • Neoplasms
  • Middle Aged
  • Microcirculation